Improving understanding of biosimilars 

The European Medicines Agency (EMA) has published additional information on biosimilar medicines, as part of their ongoing work to improve understanding of biosimilars across the EU. A biosimilar is a biological medicine that is highly similar in all essential aspects...

Pharmaceutical spending

Pharmaceutical spending accounts for approximately 20% of total health spending in OECD countries when taking into account medicines dispensed in both outpatient and inpatient settings of care. Recent developments in the pharmaceutical market and spending raise...

How Pharmaceutical Systems are organized in Asia and the Pacific 

There are important differences in the markets for medicines in countries in Asia and the Pacific in this study. These are mainly due to the political, financial and regulatory environments as well as characteristics of the pharmaceutical manufacturing industry....

EU/US collaboration on medicines and tobacco

Senior officials from the European Commission (EC), together with the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) held their 2018 bilateral meeting in Brussels, Belgium, on 18 and 19 June. The two-day bilateral regulatory...

Falsified medicines

Falsified medicines are often disguised as authentic medicines but may contain ingredients of bad or toxic quality, or in the wrong dosage. As they have not been properly checked for quality, safety and efficacy, as required by strict EU authorisation, they can pose a...